METASTATIC HER2 NEGATIVE BREAST CARCINOMA
Clinical trials for METASTATIC HER2 NEGATIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HER2 NEGATIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC HER2 NEGATIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Custom-Made vaccine targets tough cancers in early trial
⭐️ VACCINE ⭐️ Recruiting nowThis early-phase study is testing a personalized vaccine made from each patient's unique tumor mutations. The goal is to see if it is safe and can help the immune system fight advanced breast cancer, melanoma, and non-small cell lung cancer. About 25 adults whose cancers have spr…
Matched conditions: METASTATIC HER2 NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: ⭐️ VACCINE ⭐️
Last updated May 18, 2026 12:04 UTC
-
New vaccine shows promise in fight against advanced breast cancer
Disease control Recruiting nowThis study tests a vaccine called STEMVAC in people with hormone receptor-positive, HER2-negative breast cancer that has spread. The vaccine is designed to help the immune system attack cancer cells. It is given along with standard hormone therapy, a targeted drug, or chemotherap…
Matched conditions: METASTATIC HER2 NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 26, 2026 04:16 UTC
-
Smart dosing trial aims to outsmart metastatic breast cancer
Disease control Recruiting nowThis study tests a new way of giving the chemotherapy drug capecitabine to people with metastatic ER-positive, HER2-negative breast cancer. Instead of a fixed dose, the dose is adjusted based on how the tumor responds on scans and blood tests. The goal is to better control the ca…
Matched conditions: METASTATIC HER2 NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 18, 2026 12:01 UTC
-
Genetic matchmaking for cancer: ComboMATCH trial aims to personalize therapy
Knowledge-focused Recruiting nowThis study screens people with advanced solid tumors to see if their cancer has specific genetic changes. Based on those results, they may be matched to a treatment trial that targets their tumor's unique genetics. The goal is to learn how well these targeted combinations work an…
Matched conditions: METASTATIC HER2 NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 26, 2026 04:11 UTC
-
Can a PET scan predict breast cancer drug success?
Knowledge-focused Recruiting nowThis study tests whether a special PET scan can predict if a drug combination (abemaciclib plus hormone therapy) will work for people with advanced hormone receptor-positive, HER2-negative breast cancer. About 60 participants will get the treatment and have imaging scans to see i…
Matched conditions: METASTATIC HER2 NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated May 18, 2026 12:08 UTC